Key Points
- Director James Mulay sold 11,145 shares of CG Oncology on Jan. 9 at an average price of $52.47, totaling $584,778.15, per an SEC filing.
- CGON trades around $52.58 with a $4.24 billion market cap and a 12‑month range of $14.80–$57.40, and analysts hold a "Moderate Buy" consensus with a $65.58 average price target.
- Institutional interest is growing: firms like Wellington, Vanguard and Bank of America significantly increased holdings recently, and about 26.56% of the stock is owned by hedge funds and other institutional investors.
CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director James Mulay sold 11,145 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
CG Oncology Stock Down 2.1%
Shares of NASDAQ CGON opened at $52.58 on Wednesday. The company has a market capitalization of $4.24 billion, a PE ratio of -25.77 and a beta of 1.35. CG Oncology, Inc. has a twelve month low of $14.80 and a twelve month high of $57.40. The firm has a fifty day simple moving average of $41.90 and a 200 day simple moving average of $35.80.
CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.57). The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.07 million. As a group, equities analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.
Institutional Trading of CG Oncology
Several institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its position in shares of CG Oncology by 190.3% during the third quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company's stock valued at $222,055,000 after buying an additional 3,613,885 shares during the last quarter. Bank of America Corp DE lifted its stake in CG Oncology by 409.9% during the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company's stock valued at $45,156,000 after acquiring an additional 1,396,170 shares in the last quarter. Candriam S.C.A. bought a new position in CG Oncology during the 2nd quarter valued at $19,854,000. Vanguard Group Inc. boosted its holdings in CG Oncology by 11.4% during the 3rd quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company's stock worth $264,933,000 after acquiring an additional 670,770 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company's stock worth $14,597,000 after acquiring an additional 347,055 shares in the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on CGON. Royal Bank Of Canada increased their price target on CG Oncology from $53.00 to $61.00 and gave the stock an "outperform" rating in a report on Monday, November 17th. The Goldman Sachs Group reiterated a "buy" rating and set a $82.00 target price on shares of CG Oncology in a research report on Monday. Wall Street Zen raised shares of CG Oncology from a "sell" rating to a "hold" rating in a research note on Friday, October 3rd. Wedbush assumed coverage on shares of CG Oncology in a report on Thursday, December 11th. They issued an "outperform" rating and a $70.00 price target for the company. Finally, Truist Financial upped their price objective on shares of CG Oncology from $62.00 to $66.00 and gave the company a "buy" rating in a report on Friday. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $65.58.
Read Our Latest Research Report on CG Oncology
CG Oncology Company Profile
(
Get Free Report)
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
